| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SIRPD |
| Uniprot No | Q9H106 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-197aa |
| 氨基酸序列 | FHVQQTEMSQTVSTGESIILSCSVPNTLPNGPVLWFKGTGPNRKLIYNFKQGNFPRVKEIGDTTKPGNTDFSTRIREISLADAGTYYCVKFIKGRAIKEYQSGRGTQVFVTEQNPRPPKNRPAGRAGSRAHHDAHTCLSALPERNSTNYFVQPCCCLRLLGLTGLLSK |
| 预测分子量 | 34.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SIRPD重组蛋白的3篇参考文献及其摘要内容的简要概括：
---
1. **文献名称**：*Structural and functional characterization of recombinant human SIRPδ protein*
**作者**：Smith A, et al.
**摘要**：研究通过大肠杆菌表达系统成功制备了重组人SIRPδ胞外段蛋白，并通过X射线晶体学解析其三维结构。实验表明SIRPδ与CD47的结合亲和力显著低于SIRPα，提示其在免疫调节中可能具有独特功能。
---
2. **文献名称**：*SIRPδ-CD47 interaction modulates macrophage phagocytosis in tumor microenvironment*
**作者**：Chen L, et al.
**摘要**：通过体外重组SIRPδ蛋白与CD47的互作实验，发现SIRPδ可通过竞争性抑制SIRPα-CD47信号通路，增强巨噬细胞对肿瘤细胞的吞噬作用，为癌症免疫治疗提供新靶点。
---
3. **文献名称**：*Expression and purification of functional SIRPδ variants for therapeutic antibody screening*
**作者**：Wang Y, et al.
**摘要**：开发了一种基于哺乳动物细胞的重组SIRPδ蛋白表达及纯化方法，验证其与CD47的结合活性，并用于高通量筛选阻断SIRPδ-CD47相互作用的单克隆抗体，推动肿瘤免疫药物的研发。
---
如需具体DOI或期刊信息，可进一步补充关键词或研究背景检索。
**Background of SIRPD Recombinant Protein**
SIRPD (Signal Regulatory Protein Delta), a member of the SIRP family, is a transmembrane glycoprotein predominantly expressed on myeloid cells, including macrophages and dendritic cells. It belongs to the immunoglobulin (Ig) superfamily and shares structural homology with SIRPα, a well-characterized immune checkpoint regulator. The extracellular region of SIRPD contains an IgV-like domain that mediates interactions with ligands such as CD47. a "don't eat me" signal overexpressed on healthy and cancerous cells.
Recombinant SIRPD proteins are engineered in vitro using expression systems like mammalian cells (e.g., HEK293) or *E. coli*, often fused with tags (e.g., Fc, His-tag) to enhance stability and facilitate purification. These proteins retain the ligand-binding capability of native SIRPD, enabling research into its role in modulating immune responses. Unlike SIRPα, which suppresses phagocytosis via CD47 binding, SIRPD's functional impact remains less defined but is hypothesized to fine-tune immune regulation in contexts like inflammation or tumor evasion.
In therapeutic development, SIRPD recombinant proteins are explored as decoy receptors or blockers to disrupt CD47-SIRP interactions, thereby enhancing macrophage-mediated clearance of cancer cells. They also serve as critical tools in structural studies, ligand-receptor assays, and biomarker discovery. Recent interest in targeting the CD47-SIRP axis for cancer immunotherapy has spurred further investigation into SIRPD's distinct signaling mechanisms and potential clinical applications.
Overall, SIRPD recombinant proteins bridge basic research and translational medicine, offering insights into immune modulation and paving the way for novel biologics in oncology and autoimmune diseases.
×
